Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC

This study is testing a treatment approach for people with nasopharyngeal carcinoma (cancer of the back of the nasal cavity) that has come back after initial radiation treatment. It combines minimally invasive endoscopic surgery through the nose with a drug that helps the immune system fight cancer (immunotherapy). **You may be eligible if...** - You are 18 or older with confirmed recurrent nasopharyngeal carcinoma - The recurrence can be surgically removed (stages rT1–T4) - The cancer has not spread to distant parts of the body - At least 6 months have passed since you completed your original radiation treatment - Your blood counts and organ function are adequate **You may NOT be eligible if...** - The cancer has spread to distant organs or to the lining of the brain - You have an uncontrolled serious illness or autoimmune disease - You are currently taking strong immunosuppressive medications - You have previously received certain immune checkpoint drugs (like PD-1 or CTLA-4 antibodies) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.